{"id":146581,"date":"2026-04-21T15:31:04","date_gmt":"2026-04-21T19:31:04","guid":{"rendered":"https:\/\/medcitynews.com\/?p=146581"},"modified":"2026-04-21T15:31:05","modified_gmt":"2026-04-21T19:31:05","slug":"tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai","status":"publish","type":"post","link":"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/","title":{"rendered":"Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain"},"content":{"rendered":"<p>Tortugas Neuroscience launched from stealth Tuesday with <a href=\"https:\/\/www.businesswire.com\/news\/home\/20260421372757\/en\/Tortugas-Neuroscience-Launches-with-%24106-Million-to-Advance-Clinical-Stage-Pipeline-Targeting-New-and-Major-Neurology-and-Neuropsychiatric-Disorders\" target=\"_blank\" rel=\"noopener\">$106 million<\/a> to support a pipeline of four in-licensed drugs in clinical development for a range of central nervous system indications.<\/p>\n<p>The programs of Framingham, Massachusetts-based Tortugas address neuroscience targets that have been validated by already approved medications. But the startup aims to differentiate with advantages such as less frequent dosing \u2014 its drugs are all intended to be once-daily pills, which would be more convenient than some neuro medications that require multiple doses per day. Beyond offering better drug properties, the company said its molecules offer the potential for expansion to other indications.<\/p>\n<p>The two most advanced Tortugas drugs are from Hansoh Pharmaceutical Group. TRTL-107 is in Phase 2 development for schizophrenia. This molecule is a partial agonist of two dopamine receptors, D2 and D3. It\u2019s also an antagonist of 5-HT2A. While those targets are currently addressed by available antipsychotics, TRTL-107 goes after them together with a single molecule.<\/p>\n<p>The other drug from Hansoh is TRTL-913, a positive allosteric modulator of the GABAA receptor. Drugs from this class of medicines are used to treat conditions such as seizures, anxiety, and muscle spasms. Tortugas is developing TRTL-913 for tinnitus, a buzzing or hissing in the ears that\u2019s not caused by external sound. There are no FDA-approved drugs for tinnitus, though clinicians sometimes prescribe medications off-label to manage it.<\/p>\n<p>The other two clinical-stage Tortugas drugs are from Eisai. TRTL-729 is an uncompetitive GAT-1 inhibitor in mid-stage development for focal epilepsy; TRTL-118 is a PDE9 inhibitor in mid-stage development for reversible encephalopathies. The Tortuga pipeline also lists a fifth program in the discovery stage for a target and indication that remain undisclosed.<\/p>\n<p>\u201cWe believe each of our programs are well-positioned for differentiation in the marketplace,\u201d CEO Jeff Jonas said in a prepared statement. \u201cTortugas curated its pipeline for innovative therapeutics that have high potential for clinical differentiation and of reaching their target patient markets.\u201d<\/p>\n<p>Jonas and Tortugas President, Head of R&amp;D Al Robichaud are both former executives of neuroscience drug developer Sage Therapeutics. Under a multi-drug partnership with Biogen, Sage\u2019s <a href=\"https:\/\/medcitynews.com\/2023\/08\/sage-biogen-drug-is-now-the-first-approved-oral-med-for-postpartum-depression\/\" target=\"_blank\" rel=\"noopener\">Zurzuvae became the first FDA-approved oral drug for post-partum depression<\/a>. But this pill <a href=\"https:\/\/medcitynews.com\/2024\/10\/biogen-sage-therapeutics-zurzuvae-major-depressive-disorder-depression-biib\/\" target=\"_blank\" rel=\"noopener\">failed studies in major depressive disorder<\/a>, a larger indication with stronger revenue growth potential. Sage\u2019s exploration of strategy alternatives led to its <a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/06\/16\/3099695\/19871\/en\/Supernus-Pharmaceuticals-to-Acquire-Sage-Therapeutics-Strengthening-its-Neuropsychiatry-Product-Portfolio.html\" target=\"_blank\" rel=\"noopener\">acquisition by Supernus Pharmaceuticals<\/a> last year.<\/p>\n<p>The $106 million supporting Tortugas spans a seed and Series A round. Cure Ventures, where Jonas and Robichaud are partners, led the startup\u2019s seed round. Cure Ventures is also co-leading Tortugas\u2019s Series A round alongside The Column Group and AN Venture Partners. Tortugas said the funding will support ongoing R&amp;D, including the completion of Phase 2 testing of the drugs in development for schizophrenia and tinnitus.<\/p>\n<p><em>Photo by Tortugas Neuroscience<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tortugas Neurosciences\u2019 two lead programs are in-licensed oral small molecules in development for schizophrenia and tinnitus. The startup is led by veterans of Sage Therapeutics, a neuroscience biotech that was acquired last year. <\/p>\n","protected":false},"author":25932,"featured_media":146582,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"featured_image_focal_point":[],"homepage_placement":"top","homepage_placements":{"top":true,"featured":true,"sidebar":false},"homepage_alternative_layout":false,"featured_categories":[],"hide_from_feed":false,"footnotes":""},"categories":[69,60],"tags":[42355,46027,7758,10899,31365,8316,37479,53573],"class_list":["post-146581","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-startup-channel","tag-biopharma-nl","tag-deals","tag-investing","tag-neuroscience","tag-schizophrenia","tag-startups","tag-tinnitus","tag-tortugas-neuroscience"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain - MedCity News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain - MedCity News\" \/>\n<meta property=\"og:description\" content=\"Tortugas Neurosciences\u2019 two lead programs are in-licensed oral small molecules in development for schizophrenia and tinnitus. The startup is led by veterans of Sage Therapeutics, a neuroscience biotech that was acquired last year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/\" \/>\n<meta property=\"og:site_name\" content=\"MedCity News\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-21T19:31:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-21T19:31:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2026\/04\/Tortugas_Neuroscience_Jonas_Robichaud.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1393\" \/>\n\t<meta property=\"og:image:height\" content=\"929\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frank Vinluan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@frankvinluan\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frank Vinluan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/\"},\"author\":{\"name\":\"Frank Vinluan\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"headline\":\"Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain\",\"datePublished\":\"2026-04-21T19:31:04+00:00\",\"dateModified\":\"2026-04-21T19:31:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/\"},\"wordCount\":475,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2026\/04\/Tortugas_Neuroscience_Jonas_Robichaud.jpg\",\"keywords\":[\"biopharma nl\",\"Deals\",\"investing\",\"neuroscience\",\"schizophrenia\",\"Startups\",\"tinnitus\",\"Tortugas Neuroscience\"],\"articleSection\":[\"BioPharma\",\"Startups\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/\",\"url\":\"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/\",\"name\":\"Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain - MedCity News\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2026\/04\/Tortugas_Neuroscience_Jonas_Robichaud.jpg\",\"datePublished\":\"2026-04-21T19:31:04+00:00\",\"dateModified\":\"2026-04-21T19:31:05+00:00\",\"author\":{\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"breadcrumb\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/#primaryimage\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2026\/04\/Tortugas_Neuroscience_Jonas_Robichaud.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2026\/04\/Tortugas_Neuroscience_Jonas_Robichaud.jpg\",\"width\":1393,\"height\":929},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medcitynews.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medcitynews.com\/#website\",\"url\":\"https:\/\/medcitynews.com\/\",\"name\":\"MedCity News\",\"description\":\"Healthcare technology news, life science current events\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medcitynews.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\",\"name\":\"Frank Vinluan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"caption\":\"Frank Vinluan\"},\"description\":\"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/frankvinluan\/\",\"https:\/\/x.com\/frankvinluan\"],\"url\":\"https:\/\/medcitynews.com\/author\/fvinluan\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain - MedCity News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/","og_locale":"en_US","og_type":"article","og_title":"Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain - MedCity News","og_description":"Tortugas Neurosciences\u2019 two lead programs are in-licensed oral small molecules in development for schizophrenia and tinnitus. The startup is led by veterans of Sage Therapeutics, a neuroscience biotech that was acquired last year.","og_url":"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/","og_site_name":"MedCity News","article_published_time":"2026-04-21T19:31:04+00:00","article_modified_time":"2026-04-21T19:31:05+00:00","og_image":[{"width":1393,"height":929,"url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2026\/04\/Tortugas_Neuroscience_Jonas_Robichaud.jpg","type":"image\/jpeg"}],"author":"Frank Vinluan","twitter_card":"summary_large_image","twitter_creator":"@frankvinluan","twitter_misc":{"Written by":"Frank Vinluan","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/#article","isPartOf":{"@id":"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/"},"author":{"name":"Frank Vinluan","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"headline":"Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain","datePublished":"2026-04-21T19:31:04+00:00","dateModified":"2026-04-21T19:31:05+00:00","mainEntityOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/"},"wordCount":475,"commentCount":0,"image":{"@id":"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2026\/04\/Tortugas_Neuroscience_Jonas_Robichaud.jpg","keywords":["biopharma nl","Deals","investing","neuroscience","schizophrenia","Startups","tinnitus","Tortugas Neuroscience"],"articleSection":["BioPharma","Startups"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/","url":"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/","name":"Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain - MedCity News","isPartOf":{"@id":"https:\/\/medcitynews.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/#primaryimage"},"image":{"@id":"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2026\/04\/Tortugas_Neuroscience_Jonas_Robichaud.jpg","datePublished":"2026-04-21T19:31:04+00:00","dateModified":"2026-04-21T19:31:05+00:00","author":{"@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"breadcrumb":{"@id":"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/#primaryimage","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2026\/04\/Tortugas_Neuroscience_Jonas_Robichaud.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2026\/04\/Tortugas_Neuroscience_Jonas_Robichaud.jpg","width":1393,"height":929},{"@type":"BreadcrumbList","@id":"https:\/\/medcitynews.com\/2026\/04\/tortugas-neuroscience-startup-cure-ventures-schizophrenia-tinnitus-hansoh-eisai\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medcitynews.com\/"},{"@type":"ListItem","position":2,"name":"Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain"}]},{"@type":"WebSite","@id":"https:\/\/medcitynews.com\/#website","url":"https:\/\/medcitynews.com\/","name":"MedCity News","description":"Healthcare technology news, life science current events","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medcitynews.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35","name":"Frank Vinluan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/image\/","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","caption":"Frank Vinluan"},"description":"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan","sameAs":["https:\/\/www.linkedin.com\/in\/frankvinluan\/","https:\/\/x.com\/frankvinluan"],"url":"https:\/\/medcitynews.com\/author\/fvinluan\/"}]}},"_links":{"self":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/users\/25932"}],"replies":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/comments?post=146581"}],"version-history":[{"count":1,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146581\/revisions"}],"predecessor-version":[{"id":146583,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146581\/revisions\/146583"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media\/146582"}],"wp:attachment":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media?parent=146581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/categories?post=146581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/tags?post=146581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}